Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Funny, Guess they allow dogs in the office?

<< Previous

Bullboard Posts

Next >>

Comment by jfm1330on Aug 12, 2021 11:56am

103 Views

Post# 33694158

RE:RE:RE:RE:RE:RE:RE:RE:Funny, Guess they allow dogs in the office?

Simple. Come out in Q4 with excellent or spectacular efficacy results. I noticed in the chat yesterday that they did not say a word about what is actually going on with the phase Ia. They were more open during the KOL presentation, but now they are at the stage where they know more on critical stuff. It is very important for them to release any info about the trial in the proper manner, by press release and outside of trading hours.